# Johannes Fruehauf

> Johannes Fruehauf is a Series A investor at LabCentral backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [LabCentral](https://shizune.co/investors/profile/labcentral)
- Location: Boston, United States
- Total investments: 7
- Last investment: Oct 2025
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/johannesfruehauf
- X (Twitter): https://twitter.com/JFruehauf
- Website: https://x.com/JFruehauf

Johannes Fruehauf is a Series A investor at LabCentral in Boston focused on Biotechnology and Health Care. Johannes Fruehauf is the Founder & CEO LabCentral/Biolabs.He is responsible for all aspects of LabCentral’s operation. Johannes is a physician and successful biotech entrepreneur. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. He was also aco-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits. Johannes earned his medical degree at the University of Frankfurt and his PhD at the University of Heidelberg (Germany).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Health Care | 3 | 43% |
| Therapeutics | 2 | 29% |
| Medical | 1 | 14% |
| Consumer | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 57% |
| Seed | 1 | 14% |
| Series B | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zag Bio | Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M | Series A | Oct 28, 2025 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M | Series B | Mar 09, 2023 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $42M | Series A | May 13, 2020 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $5.5M | Seed | Nov 19, 2018 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $5.5M | Seed | Nov 19, 2018 |  |
| Sentien Biotechnologies | Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extendtherapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States. | $12M | Series A | Apr 04, 2017 |  |
| Sentieon | Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include SentieonDNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation.The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California. | $3.8M | Series A | Apr 04, 2014 |  |

7 of 7 investments shown.

## Co-investors
- [MP Healthcare Venture Management](https://shizune.co/investors/profile/mp-healthcare-venture-management-inc) — VC Fund, 4 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 3 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 3 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 2 deals together
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 2 deals together

## About LabCentral

VC Fund · Hardwick, United States

LabCentral developing novel cancer treatments: Conkwest, Inc, headquartered in DelMar, California, is opening its research laboratory at LabCentral. Conkwest is an innovative life sciences company that is developing and commercializing cell based treatments for cancer and viral infections.

5 contacts available at LabCentral.

| Name | Title | Profile |
| --- | --- | --- |
| Gretchen Cook-Anderson | Executive Director, Ignite | https://shizune.co/investors/profile/gretchen-cook-anderson |
| Johannes Fruehauf | Founder, President & Executive Director | https://shizune.co/investors/profile/johannes-fruehauf |
| Johannes Fruehauf | Founder, President & Executive Director | https://shizune.co/investors/profile/johannes-fruehauf-1042 |
| Peter Parker | Co-Founder & Director | https://shizune.co/investors/profile/peter-parker |
| Tim Rowe | Chairman and CEO | https://shizune.co/investors/profile/timothy-rowe |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Johannes Fruehauf invest in?

Johannes Fruehauf invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Johannes Fruehauf last invest?

The most recent investment recorded for Johannes Fruehauf closed in Oct 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co